Related Experiment Videos
Angiogenesis research: from laboratory to clinic
1Children's Hospital and Harvard Medical School, Boston, Massachusetts.
Forum (Genoa, Italy)
|December 23, 1999
Summary
Inhibiting tumour angiogenesis, the formation of new blood vessels, can halt cancer growth. This approach offers a promising strategy to reduce toxicity and improve anti-cancer efficacy.
Area of Science:
- Oncology
- Vascular Biology
Background:
- Tumour growth and lethality are critically dependent on angiogenesis.
- Angiogenesis inhibitors can limit tumour size to a dormant, harmless state in animal models.
Purpose of the Study:
- To review recent evidence supporting the role of vascular endothelial cells in tumour growth control.
- To explore the potential of anti-angiogenic therapies as adjuncts to conventional cancer treatments.
Main Methods:
- Administration of specific angiogenesis inhibitors targeting proliferating vascular endothelium.
- Optimization and targeted delivery of cytotoxic chemotherapy to tumour vascular endothelium.
- Sensitization of tumour vascular endothelium to radiotherapy using angiogenesis inhibitors.
Main Results:
- Experimental evidence demonstrates that inhibiting angiogenesis can effectively control tumour growth.
- Targeting vascular endothelial cells offers multiple therapeutic strategies for cancer treatment.
Conclusions:
- Anti-angiogenic therapy holds significant potential to reduce cancer toxicity and drug resistance.
- Future cancer treatment may involve combining angiogenesis inhibitors with chemotherapy, radiotherapy, immunotherapy, or gene therapy for enhanced efficacy.